Bezisterim
Asset
Oral anti-inflammatory insulin-sensitizing neurosteroid agent modulating NF-kB and DNA promoter methylation
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- NF-κB signalling
- 4
- Indications
- 0
- Trials
- 1
- Developer
Indications
4Alzheimer's disease
Phase 2, doi.org, 5 Jun 2026
Parkinson's disease
Phase 2, doi.org, 5 Jun 2026
Long COVID
Human trials, doi.org, 5 Jun 2026
1 more
In the full profile
- Targets and what it contains3
- Owner and partners3
- Evidence for its targets4
- Competitors12
- Aging relevance2
- Signals3
Every asset’s record: target, stage, trials and the evidence behind it.